Human Metapneumovirus Hmpv Diagnostics Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

HMPV diagnostics include nucleic acid amplification tests, immunoassays, and point-of-care rapid tests designed to identify human metapneumovirus infection. The virus, a member of the Pneumoviridae family closely related to respiratory syncytial virus, has emerged as a significant cause of acute respiratory infection worldwide. Growing clinical recognition of HMPV's disease burden has spurred investment in diagnostic infrastructure and test development.

• •The global market was valued at approximately $0.61 billion in 2025
• •Projected to grow at a compound annual growth rate of 10.4% through the early 2030s
• •Covers molecular tests, antigen detection kits, and serology-based diagnostics

An aging global population with higher susceptibility to severe respiratory illness is a primary demand driver. Simultaneously, increased investment in multiplex respiratory panel testing that includes HMPV alongside influenza, RSV, and SARS-CoV-2 has expanded testing volumes. Additionally, rising healthcare spending in emerging markets and improved access to molecular diagnostics in hospital and laboratory settings are fueling adoption.

• •Growing elderly population and prevalence of immunocompromised patients driving demand for comprehensive respiratory testing
• •Multiplex PCR panels bundling HMPV with other respiratory pathogens are becoming standard of care in many hospitals
• •Increased clinical awareness and publication of HMPV disease burden data since its discovery in 2001

By technology, molecular diagnostics dominates due to the high accuracy of PCR-based testing, followed by rapid antigen tests favored in point-of-care settings. Geographically, North America leads due to advanced healthcare infrastructure and high testing rates, while Europe and the Asia-Pacific region are growing rapidly as diagnostic access improves in countries such as China, India, and Japan.

• •North America holds the largest market share, with the U.S. being the primary driver
• •Asia-Pacific is the fastest-growing region due to expanding laboratory infrastructure and rising disease awareness
• •Molecular diagnostics segment is projected to outpace other technologies through the forecast period

What are the recent trends and outlook?

The market is expected to see continued consolidation of respiratory testing into comprehensive syndromic panels, reducing the incremental cost of adding HMPV to existing workflows. Advances in next-generation sequencing and point-of-care molecular platforms may further lower barriers to testing. The ongoing legacy of the COVID-19 pandemic has permanently elevated respiratory virus surveillance, supporting sustained investment in HMPV diagnostics through the forecast horizon.

• •Shift toward syndromic respiratory panels that simultaneously detect HMPV, RSV, influenza, and other pathogens
• •Development of rapid, near-patient molecular tests to bring HMPV diagnostics outside traditional laboratory settings
• •Long-term market supported by pandemic-era improvements in respiratory virus surveillance infrastructure